Middle East & Africa Vaccine Adjuvants Market Forecast to 2030 – Regional Analysis – by Adjuvant Class (Mineral Salt Adjuvant, Emulsion Adjuvant, Liposome Adjuvant, and Others) and Type (Human Vaccine Adjuvant and Veterinary Vaccine Adjuvant)
The Middle East & Africa vaccine adjuvants market was valued at US$ 78.94 million in 2022 and is expected to reach US$ 187.15 million by 2030; it is estimated to register a CAGR of 11.4% from 2022 to 2030.
Technological Advancements Bolster Middle East & Africa Vaccine Adjuvants Market
Currently, aluminum salt or gel-based adjuvants are used predominantly in licensed vaccines. Monophosphoryl lipid A (MPL) adjuvant and hydrophobic copolymers are examples of these components. Hydrophobic microspheres pose challenges during vaccine production. The problems include many environmental waste disposal and contamination issues and are time-consuming, costly, and inefficient. Therefore, manufacturers are emphasizing developing novel technologies to avoid using organic solvents. For example, Aphios’ Vaccine Adjuvant Technology encompasses nanotechnology, and its production includes supercritical, critical, or near-critical fluids with or without polar cosolvents such as ethanol [referred to as superfluids (SFS)]. Biodegradable biopolymers are dissolved in SFS and mixed with subunit vaccines in an aqueous solution or as a slurry of nanoparticles. Therefore, such new vaccine adjuvant technologies are being developed for making biodegradable polymer nanospheres (PNS) through novel processes, which allows vaccine manufacturers to rule out the use of organic solvents. Thus, technological advancements will likely bring new trends in the vaccine adjuvants market in the coming years.
Middle East & Africa Vaccine Adjuvants Market Overview
The Middle East & Africa vaccine adjuvant market has been segmented into Saudi Arabia, South Africa, the UAE, and the Rest of Middle East & Africa. An increase in product approvals is a major driver for the positive growth of the vaccine adjuvants market in Saudi Arabia. The product approvals by the SAFDA will enhance the adoption of adjuvanted vaccines and accelerate their adoption in the coming years in Saudi Arabia, propelling the market growth from 2020 to 2030.
Middle East & Africa Vaccine Adjuvants Market Revenue and Forecast to 2030 (US$ Million)
Get more information on this report :
Middle East & Africa Vaccine Adjuvants Market Segmentation
The Middle East & Africa vaccine adjuvants market is categorized into adjuvant class, type, and country.
Based on adjuvant class, the Middle East & Africa vaccine adjuvants market is segmented into mineral salt adjuvant, emulsion adjuvant, liposome adjuvant, and others. The mineral salt adjuvant segment held the largest share of the Middle East & Africa vaccine adjuvants market share in 2022.
By type, the Middle East & Africa vaccine adjuvants market is bifurcated into human vaccine adjuvant and veterinary vaccine adjuvant. The human vaccine adjuvant segment held a larger share of Middle East & Africa vaccine adjuvants market in 2022.
By country, the Middle East & Africa vaccine adjuvants market is segmented into Saudi Arabia, South Africa, the UAE, and the Rest of Middle East & Africa. Saudi Arabia dominated the Middle East & Africa vaccine adjuvants market share in 2022.
Croda International Plc; CSL Ltd; GSK Plc; Novavax Inc; and Phibro Animal Health Corp are some of the leading companies operating in the Middle East & Africa vaccine adjuvants market.
1. Introduction
1.1 The Insight Partners Research Report Guidance
1.2 Market Segmentation
2. Executive Summary
2.1 Key Insights
3. Research Methodology
3.1 Coverage
3.2 Secondary Research
3.3 Primary Research
4. Middle East & Africa Vaccine Adjuvants Market – Key Market Dynamics
4.1 Middle East & Africa Vaccine Adjuvants Market – Key Market Dynamics
4.2 Market Drivers
4.2.1 Rising Number of Infectious Disease Outbreaks and Pandemic
4.2.2 Approvals of Veterinary Vaccine Adjuvants
4.3 Market Restraints
4.3.1 Product Recalls and Adverse Effects
4.4 Market Opportunities
4.4.1 Advancements in Biotechnology and Immunology
4.5 Future Trends
4.5.1 Technological Advancements
4.6 Impact of Drivers and Restraints:
5. Vaccine Adjuvants Market –Middle East & Africa Market Analysis
5.1 Middle East & Africa Vaccine Adjuvants Market – Revenue and Forecast to 2030 (US$ Million)
5.2 Middle East & Africa Vaccine Adjuvants Market Forecast and Analysis
6. Middle East & Africa Vaccine Adjuvants Market Analysis –by Adjuvant Class
6.1 Overview
6.2 Mineral Salt Adjuvant
6.2.1 Overview
6.2.2 Mineral Salt Adjuvant: Middle East & Africa Vaccine Adjuvants Market – Revenue and Forecast to 2030 (US$ Million)
6.3 Emulsion Adjuvant
6.3.1 Overview
6.3.2 Emulsion Adjuvant: Middle East & Africa Vaccine Adjuvants Market – Revenue and Forecast to 2030 (US$ Million)
6.4 Liposome Adjuvant
6.4.1 Overview
6.4.2 Liposome Adjuvant: Middle East & Africa Vaccine Adjuvants Market – Revenue and Forecast to 2030 (US$ Million)
6.5 Others
6.5.1 Overview
6.5.2 Others: Middle East & Africa Vaccine Adjuvants Market – Revenue and Forecast to 2030 (US$ Million)
7. Middle East & Africa Vaccine Adjuvants Market Analysis – by Type
7.1 Human Vaccine Adjuvant
7.1.1 Overview
7.1.2 Human Vaccine Adjuvant: Middle East & Africa Vaccine Adjuvants Market – Revenue and Forecast to 2030 (US$ Million)
7.2 Veterinary Vaccine Adjuvant
7.2.1 Overview
7.2.2 Veterinary Vaccine Adjuvant: Middle East & Africa Vaccine Adjuvants Market – Revenue and Forecast to 2030 (US$ Million)
8. Middle East & Africa Vaccine Adjuvants Market –Country Analysis
8.1 Middle East & Africa
8.1.1 Middle East & Africa: Vaccine Adjuvants Market – Revenue and Forecast Analysis – by Country
8.1.1.1 Saudi Arabia: Vaccine Adjuvants Market – Revenue and Forecast to 2030 (US$ Million)
8.1.1.1.1 Overview
8.1.1.1.2 Saudi Arabia: Vaccine Adjuvants Market – Revenue and Forecast to 2030 (US$ Million)
8.1.1.1.3 Saudi Arabia: Vaccine Adjuvants Market Breakdown, by Adjuvant Class
8.1.1.1.4 Saudi Arabia: Vaccine Adjuvants Market Breakdown, by Type
8.1.1.2 South Africa: Vaccine Adjuvants Market – Revenue and Forecast to 2030 (US$ Million)
8.1.1.2.1 Overview
8.1.1.2.2 South Africa: Vaccine Adjuvants Market – Revenue and Forecast to 2030 (US$ Million)
8.1.1.2.3 South Africa: Vaccine Adjuvants Market Breakdown, by Adjuvant Class
8.1.1.2.4 South Africa: Vaccine Adjuvants Market Breakdown, by Type
8.1.1.3 United Arab Emirates: Vaccine Adjuvants Market – Revenue and Forecast to 2030 (US$ Million)
8.1.1.3.1 Overview
8.1.1.3.2 United Arab Emirates: Vaccine Adjuvants Market – Revenue and Forecast to 2030 (US$ Million)
8.1.1.3.3 United Arab Emirates: Vaccine Adjuvants Market Breakdown, by Adjuvant Class
8.1.1.3.4 United Arab Emirates: Vaccine Adjuvants Market Breakdown, by Type
8.1.1.4 Rest of Middle East and Africa Vaccine Adjuvants Market – Revenue and Forecast to 2030 (US$ Million)
8.1.1.4.1 Overview
8.1.1.4.2 Rest of Middle East and Africa Vaccine Adjuvants Market – Revenue and Forecast to 2030 (US$ Million)
8.1.1.4.3 Rest of Middle East and Africa Vaccine Adjuvants Market Breakdown, by Adjuvant Class
8.1.1.4.4 Rest of Middle East and Africa Vaccine Adjuvants Market Breakdown, by Type
9. Industry Landscape
9.1 Overview
9.2 Growth Strategies in the Global Vaccine Adjuvants Market
9.3 Organic Developments
9.3.1 Overview
9.4 Inorganic Developments
9.4.1 Overview
10. Company Profiles
10.1 GSK Plc
10.1.1 Key Facts
10.1.2 Business Description
10.1.3 Products and Services
10.1.4 Financial Overview
10.1.5 SWOT Analysis
10.1.6 Key Developments
10.2 CSL Ltd
10.2.1 Key Facts
10.2.2 Business Description
10.2.3 Products and Services
10.2.4 Financial Overview
10.2.5 SWOT Analysis
10.2.6 Key Developments
10.3 Croda International Plc
10.3.1 Key Facts
10.3.2 Business Description
10.3.3 Products and Services
10.3.4 Financial Overview
10.3.5 SWOT Analysis
10.3.6 Key Developments
10.4 Novavax Inc
10.4.1 Key Facts
10.4.2 Business Description
10.4.3 Products and Services
10.4.4 Financial Overview
10.4.5 SWOT Analysis
10.4.6 Key Developments
10.5 Phibro Animal Health Corp
10.5.1 Key Facts
10.5.2 Business Description
10.5.3 Products and Services
10.5.4 Financial Overview
10.5.5 SWOT Analysis
10.5.6 Key Developments
11. Appendix
11.1 About The Insight Partners
List of Tables
Table 1. Middle East & Africa Vaccine Adjuvants Market Segmentation
Table 2. Middle East & Africa Vaccine Adjuvants Market Revenue and Forecasts To 2030 (US$ Million)
Table 3. Saudi Arabia: Vaccine Adjuvants Market – Revenue and Forecast to 2030(US$ Million) – by Adjuvant Class
Table 4. Saudi Arabia: Vaccine Adjuvants Market – Revenue and Forecast to 2030(US$ Million) – by Type
Table 5. South Africa: Vaccine Adjuvants Market – Revenue and Forecast to 2030(US$ Million) – by Adjuvant Class
Table 6. South Africa: Vaccine Adjuvants Market – Revenue and Forecast to 2030(US$ Million) – by Type
Table 7. United Arab Emirates: Vaccine Adjuvants Market – Revenue and Forecast to 2030(US$ Million) – by Adjuvant Class
Table 8. United Arab Emirates: Vaccine Adjuvants Market – Revenue and Forecast to 2030(US$ Million) – by Type
Table 9. Rest of Middle East and Africa Vaccine Adjuvants Market – Revenue and Forecast to 2030(US$ Million) – by Adjuvant Class
Table 10. Rest of Middle East and Africa Vaccine Adjuvants Market – Revenue and Forecast to 2030(US$ Million) – by Type
Table 11. Organic Developments Done by Companies
Table 12. Inorganic Developments Done by Companies
List of Figures
Figure 1. Middle East & Africa Vaccine Adjuvants Market Segmentation, by Country
Figure 2. Impact Analysis of Drivers and Restraints
Figure 3. Middle East & Africa Vaccine Adjuvants Market Revenue (US$ Million), 2022–2030
Figure 4. Middle East & Africa Vaccine Adjuvants Market Share (%) – by Adjuvant Class (2022 and 2030)
Figure 5. Mineral Salt Adjuvant: Middle East & Africa Vaccine Adjuvants Market – Revenue and Forecast to 2030 (US$ Million)
Figure 6. Emulsion Adjuvant: Middle East & Africa Vaccine Adjuvants Market – Revenue and Forecast to 2030 (US$ Million)
Figure 7. Liposome Adjuvant: Middle East & Africa Vaccine Adjuvants Market – Revenue and Forecast to 2030 (US$ Million)
Figure 8. Others: Middle East & Africa Vaccine Adjuvants Market – Revenue and Forecast to 2030 (US$ Million)
Figure 9. Middle East & Africa Vaccine Adjuvants Market Share (%) – by Type (2022 and 2030)
Figure 10. Human Vaccine Adjuvant: Middle East & Africa Vaccine Adjuvants Market – Revenue and Forecast to 2030 (US$ Million)
Figure 11. Veterinary Vaccine Adjuvant: Middle East & Africa Vaccine Adjuvants Market – Revenue and Forecast to 2030 (US$ Million)
Figure 12. Middle East and Africa Vaccine Adjuvants Market by Key Countries – Revenue 2022 (US$ Million)
Figure 13. Middle East and Africa Vaccine Adjuvants Market Breakdown, by Key Countries, 2022 and 2030 (%)
Figure 14. Saudi Arabia: Vaccine Adjuvants Market – Revenue and Forecast to 2030(US$ Million)
Figure 15. South Africa: Vaccine Adjuvants Market – Revenue and Forecast to 2030(US$ Million)
Figure 16. United Arab Emirates: Vaccine Adjuvants Market – Revenue and Forecast to 2030(US$ Million)
Figure 17. Rest of Middle East and Africa Vaccine Adjuvants Market – Revenue and Forecast to 2030(US$ Million)
Figure 18. Growth Strategies in the Vaccine Adjuvants Market
- Croda International Plc
- CSL Ltd
- GSK Plc
- Novavax Inc
- Phibro Animal Health Corp
- Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the Middle East & Africa vaccine adjuvants market.
- Highlights key business priorities to assist companies to realign their business strategies.
- The key findings and recommendations highlight crucial progressive industry trends in the Middle East & Africa vaccine adjuvants market, thereby allowing players across the value chain to develop effective long-term strategies.
- Develop/modify business expansion plans by using substantial growth offering developed and emerging markets
- Scrutinize in-depth Middle East & Africa market trends and outlook coupled with the factors driving the Middle East & Africa vaccine adjuvants market, as well as those hindering it.
- Enhance the decision-making process by understanding the strategies that underpin commercial interest with respect to client products, segmentation, pricing, and distribution.